Figure 5.
DRrejTs robustly suppressed LCLs
(A) Bioluminescence imaging of mice treated with LMP2-rejTs, CD19-CAR-transduced HPV-rejTs (CD19-CAR/HPV-rejTs), or DRrejTs. EBV+ LCL-bearing mice were divided into four groups that received no treatment (n = 5), LMP2-rejTs (n = 4), CD19-CAR/HPV-rejTs (n = 4), or DRrejTs (n = 6). No treatment indicates mice that were injected with LCL cells but not treated with T cells. LMP2-rejTs, CD19-CAR/HPV-rejTs, or DRrejTs (4 × 106 cells) were injected intraperitoneally once a week (three doses). Images of all mice from each group of two independent experiments are shown. (B) Quantification of tumor burden on day 18 is represented. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 by one-way ANOVA. (C) Kaplan-Meier curve representing percentage survival of the experimental groups: no treatment, LMP2-rejTs, CD19-CAR/HPV-rejTs, or DRrejTs. ∗p < 0.05, ∗∗p < 0.01 by log-rank test. (D) Flow cytometric analyses of peripheral blood of LMP2-rejT (day 42)-, CD19-CAR/HPV-rejT (day 23)-, or DRrejT (day 42)-treated LCL-inoculated mice. The plots represent three independent experiments. (E) CD19-CARs persisted in peripheral blood of mice treated with CD19-CAR/HPV-rejTs on day 23 or DRrejTs on day 48. Copy number of CD19-CAR-transduced T cells, positive control. Error bars represent ± SD. ∗∗∗∗p < 0.0001 by one-way ANOVA. Data represent three independent triplicate experiments.